Posted on October 15th, 2009 by Kelley Luckstein
Interim data with donepezil administered to patients in the Mayo Acute Stroke Trial to Enhance Recovery (MASTER) supports advancement into stage 2, according to a report presented here at the American Neurological Association (ANA) 134th Annual Meeting…
The objective of this study was to develop donepezil hydrochloride as a novel pharmacotherapy to enhance poststroke recovery, reported Kevin M. Barrett, MD, Mayo Clinic, Jacksonville, Florida, on October 12.
"Donepezil improves cognitive performance in vascular dementia, and smaller studies suggest benefit in poststroke aphasia and motor recovery," said James F. Meschia, MD, Mayo Clinic, Jacksonville, Florida.
Doctors Guide by Crina Frincu-Mallos, PhD, 10/14/09
You must be logged-in to the site to post a comment.